CompanyDrug

BMS’s Opdivo Approved in China for Neoadjuvant Therapy in Urothelial Carcinoma

Policy / Regulatory

NHSA Updates 2022 National Reimbursement Drug List with 2,967 Drug Varieties

CompanyDrug

Harbour BioMed Receives FDA Approval for HBM1007 Clinical Study

CompanyDrug

Joincare’s Biosimilar Tocilizumab Approved for Marketing in China

CompanyDrug

CANbridge Pharmaceuticals Initiates Phase II Dosing for CAN103 in Gaucher Disease

CompanyDeals

GenScript ProBio Closes $220M Series C Financing for Biologics and Gene Therapy Expansion

CompanyDeals

Roche and HKSTP Collaborate to Boost Life Sciences in Greater Bay Area

Company

Burning Rock Upgrades 2022 Revenue Growth Forecast to 10% YOY

CompanyDeals

Pasithea Therapeutics Partners with WuXi AppTec for API Manufacturing of PAS-004

Policy / Regulatory

NHSA Completes 2022 NRDL Update with 111 New Listings, Focus on COVID-19 Treatments

CompanyDrug

CDE Grants Priority Review to Takeda’s Vonicog Alfa, Zhongmei’s Rilonacept, and Zai Lab’s SUL-DUR

CompanyDrug

Immunofoco’s CLDN18.2-Targeted CAR-T Therapy IMC002 Accepted for CDE Review